ReuterinaContact Details
Overview
Reuterina is a probiotic supplement range that has historically been associated with the South African pharmaceutical and healthcare company Ascendis Health. Public, up‑to‑date contact details that are specifically branded as “Reuterina” are not published as a standalone set of channels (such as a dedicated Reuterina call centre or email). Instead, product‑related queries are typically routed via Ascendis Health’s corporate contact points and customer‑care details.
Below is a summary of the most verifiable, public contact details relevant to Reuterina in South Africa, based on official and reputable online sources.
Main Corporate Contact for Reuterina (Ascendis Health)
Because Reuterina is listed as a product within Ascendis Health’s portfolio, the primary and most reliable route for Reuterina‑related enquiries is via Ascendis Health’s head‑office and corporate contact channels.
Registered / Physical Address
The Ascendis Health head‑office address (as listed in official company communications) is:
Ascendis Health Limited
Address: 1st Floor, Block D, Cambridge Manor Office Park, 5 Bauhinia Street, Highveld Techno Park, Centurion, 0157, South Africa
This address is published in Ascendis Health’s company announcements on the Johannesburg Stock Exchange news service, for example in a 2024 circular where Ascendis Health lists its registered office as “1st Floor, Block D, Cambridge Manor Office Park, 5 Bauhinia Street, Highveld Techno Park, Centurion, 0157” (JSE SENS circular – Ascendis Health).
Postal Address
In the same official documents, Ascendis Health provides a postal address for correspondence:
Postal Address:
PO Box 4896, Halfway House, 1685, South Africa
This postal address appears in the Ascendis Health shareholder communication where the company lists its “postal address: PO Box 4896, Halfway House, 1685” as part of the corporate information section (Ascendis Health circular on JSE SENS).
Website
Ascendis Health operates its corporate website at:
- Website: https://ascendishealth.com
This URL is given as the official company website in Ascendis Health’s corporate and investor‑relations communications; for example, the corporate overview page lists Ascendis Health divisions and brands via “Our Brands” at Ascendis Health official site.
While Reuterina is not always named prominently on the public‑facing site, the corporate site remains the most authoritative hub for product‑related and investor‑related contact.
Email Contacts (Corporate & Investor / Governance)
Ascendis Health publicly lists email contacts mainly for corporate governance, not consumer product support. However, these can serve as a starting point if you need to reach the company and do not have a retailer or pharmacy channel:
- Company Secretary / Governance:
Ascendis Health’s circular to shareholders lists “company.secretarial@ascendishealth.com” as the contact email address for company‑secretarial matters and corporate governance queries (Ascendis Health SENS circular). - General Website Contact Form:
The Ascendis Health website has a general contact page where you can submit enquiries via an online form, which can be used for Reuterina‑related questions. This is accessible through the “Contact” navigation on the Ascendis Health website.
At the time of research, no dedicated Reuterina‑only email address was publicly listed in credible sources. For product‑specific issues, contacting Ascendis Health through the general web form and clearly stating the product name “Reuterina” in your subject and message is the most direct route.
Telephone Numbers
Recent official corporate filings and circulars focus primarily on email and addresses; no consumer‑facing Reuterina phone line is listed in credible public records. Older or third‑party directory listings sometimes carry generic or outdated Ascendis numbers, but these are not consistently confirmed in current official filings.
Because of this, the safest recommendation is:
- Use the online contact form on Ascendis Health’s official website and request a call‑back for Reuterina queries; or
- Ask your pharmacist or healthcare provider to provide the current medical information or medical‑information line used for Ascendis‑branded products.
How to Use These Contact Details for Reuterina Queries
1. Using the Ascendis Health Website Contact Form
Best for:
- Product information on Reuterina (ingredients, usage, storage).
- Reporting suspected side effects or quality issues.
- Queries about product availability, discontinuation, or rebranding.
Steps:
- Visit the Ascendis Health website.
- Navigate to the Contact or Get in touch section.
- In your message, clearly include:
- The product name: “Reuterina” (and specify which variant, e.g., Reuterina Infant, Reuterina Daily, etc., if applicable).
- Batch/lot number and expiry date (from packaging), if you are reporting a product issue.
- Where you bought the product (pharmacy chain, store, online platform) and in which city/province.
- Your preferred contact details (email and/or phone number).
This channel is appropriate for non‑urgent medical questions or general product support.
2. Writing to the Postal Address
Best for:
- Formal complaints or legal correspondence regarding Reuterina.
- Requests that require original documents or signed forms.
Address your letter to:
Ascendis Health Limited
(Attention: Customer Care / Reuterina Product Enquiry)
PO Box 4896
Halfway House
1685
South Africa
Include copies (not originals) of any relevant receipts, packaging, or medical notes if your query relates to product quality or an adverse reaction.
3. Visiting or Couriering to the Registered Office
For highly formal matters—such as delivering legal notices, regulatory complaints, or corporate collaboration proposals—you may use the registered office:
Ascendis Health Limited
1st Floor, Block D
Cambridge Manor Office Park
5 Bauhinia Street
Highveld Techno Park
Centurion
0157
South Africa
This address is taken from Ascendis Health’s formal corporate circulars filed via the JSE news service (Ascendis Health’s JSE SENS circular).
Which Department to Contact for Reuterina‑Related Issues
Because Ascendis Health does not publicly break out Reuterina as a separate business unit online, you will typically be routed to one of the following internal functions when you make contact through corporate channels.
Product / Medical Information
When to use this route:
- Questions about dosage, age‑appropriateness (e.g., infants vs adults), and contraindications.
- Clarification on interactions with other medicines.
- Queries about side effects or whether to stop use.
How to reach them:
- Submit a query via the online contact form on Ascendis Health’s site and clearly label your query as “Medical information – Reuterina”.
- Your pharmacist or healthcare provider may also have a healthcare‑professional‑only medical information number for Ascendis‑linked products, which is often shared through professional channels rather than public web pages.
Quality Complaints / Pharmacovigilance
When to use this route:
- If you suspect the product is defective (e.g., unusual smell, damaged packaging, clumping, or foreign matter).
- If you or someone else experienced a suspected adverse reaction potentially related to Reuterina.
What to prepare:
- Product name and variant.
- Batch/lot number and expiry date.
- Where and when you purchased the product.
- Description of the quality issue or adverse event, including dates and any medical treatment received.
How to reach them:
- Use the general contact form on Ascendis Health’s official website and ask that your report be forwarded to the pharmacovigilance or quality department.
- Alternatively, lodge the issue via your dispensing pharmacy, which has obligations to forward serious safety concerns to suppliers and regulators.
Corporate / Investor‑Related Queries
When to use this route:
- Questions about corporate ownership of Reuterina.
- Media or investor‑relations queries concerning the Reuterina product portfolio.
How to reach them:
- Use the company.secretarial@ascendishealth.com email listed in the company’s shareholder circular for corporate governance queries (Ascendis governance email in SENS circular).
- Clearly state that you are contacting them with a media/investor enquiry involving Reuterina.
Escalation Options for Reuterina Queries in South Africa
If you are not satisfied with the response received from Ascendis Health or through pharmacy channels, you have further escalation routes in South Africa.
1. Pharmacist and Prescribing Healthcare Professional
For any clinical concerns (e.g., side effects, lack of efficacy, interactions), your first line of escalation should be:
- The pharmacist who dispensed/sold the product.
- The doctor or healthcare professional who recommended or prescribed Reuterina.
They can advise on whether to discontinue use, switch products, or report an adverse event through clinical channels.
2. South African Health Products Regulatory Authority (SAHPRA)
Reuterina, as a health product supplied in South Africa, ultimately falls within the oversight of the South African Health Products Regulatory Authority (SAHPRA), which provides channels for reporting adverse events and product‑quality problems.
- SAHPRA’s official site is https://www.sahpra.org.za.
- On the site, the “Report an adverse drug reaction (ADR)” and complaint forms guide consumers and healthcare professionals on how to report suspected safety or quality issues with medicines and health products (SAHPRA official website).
When escalating to SAHPRA, include:
- Product name (Reuterina and variant).
- Batch/lot number and expiry date.
- Detailed description of the event or issue and relevant medical information.
3. Consumer Protection Structures
If your complaint is more about misleading marketing, pricing disputes, or retail experience, you may consider:
- The Consumer Goods and Services Ombud (CGSO), which deals with consumer complaints about suppliers of goods and services in South Africa. Their details and complaint forms are available on the CGSO official website.
- The National Consumer Commission (NCC) for serious consumer‑rights infringements under the Consumer Protection Act, via channels listed on the NCC official site.
In each case, keep:
- Proof of purchase.
- All correspondence with the retailer and with Ascendis Health (emails, reference numbers).
Practical Tips When Contacting Reuterina (via Ascendis Health)
- Be specific about the product.
State “Reuterina” plus any sub‑brand (e.g., Reuterina Infant) so your query can be routed correctly. -
Keep packaging and receipts.
Batch numbers, expiry dates, and purchase records help Ascendis or regulators investigate complaints. -
Use written channels where possible.
The web contact form and email provide a written record, which is useful for follow‑up and any escalation. -
Differentiate between medical and administrative queries.
- Medical and safety concerns → explain symptoms, other medicines in use, and timing.
- Administrative issues (availability, pricing, promotions) → include store details, dates, and any promotional materials.
- If you need urgent medical help, do not rely on email.
For serious or acute reactions, seek immediate attention from a doctor, emergency room, or emergency services, and only then follow up with Ascendis Health or SAHPRA using the channels above.
Summary
Because “ReuterinaContact Details” are not published as a separate brand‑specific set of contact points, the most reliable and verifiable route is via Ascendis Health Limited, using:
- Registered office address and postal address as confirmed in Ascendis Health’s official SENS circular (Ascendis Health – JSE SENS circular).
- The Ascendis Health corporate website at https://ascendishealth.com, including its contact form for product enquiries.
- The company.secretarial@ascendishealth.com email from governance filings for corporate‑level queries.
For serious safety concerns or unresolved product‑quality complaints about Reuterina, escalation is available via SAHPRA (SAHPRA official website) and, for consumer‑rights issues, via bodies such as the CGSO (CGSO official site) or NCC (NCC official site).
All contact attempts should clearly identify Reuterina as the product of concern and include as much factual detail as possible to ensure your query is handled efficiently.
Leave a Reply